Nkarta reports fourth quarter and full year 2020 financial results and highlights business progress

South san francisco, calif., march 25, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended december 31, 2020.
NKTX Ratings Summary
NKTX Quant Ranking